|
|
Vaccine Detail
|
Synchrotope TA2M Plasmid DNA Vaccine |
| Vaccine Information |
- Vaccine Name: Synchrotope TA2M Plasmid DNA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007109
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: Tyrosinase
- Tyrosinase
gene engineering:
- Preparation: Synchotrope TA2M™ is a recombinant plasmid DNA vaccine that encodes two peptides, tyrosinase 207–216 and tyrosinase 1–17, both of which are derived from human tyrosinase. The backbone for TA2M has two copies of the murine CpG immune stimulatory sequence AACGTT inserted (Tagawa et al., 2003).
- Description: This is for Melanoma Cancer (NCT00023647). A recombinant plasmid DNA vaccine encoding epitopes of tyrosinase with potential antineoplastic activity. Synchrotope TA2M vaccine contains a plasmid encoding 2 epitopes, amino acid sequences 207-216 and 1-17 of tyrosinase, a protein frequently expressed by melanoma cells. Vaccination with the TA2M plasmid DNA vaccine may induce the production of anti-tyrosinase antibodies as well as elicit a cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells, resulting in decreased tumor growth (NCIT_C2650).
|
| Host Response |
|
|
| References |
NCIT_C2650: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2650]
NCT00023647: [https://clinicaltrials.gov/show/NCT00023647]
Tagawa et al., 2003: Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003; 98(1); 144-154. [PubMed: 12833467].
|
|
